Bluebird bio Inc Cash Flow Conversion Efficiency
Bluebird bio Inc cash flow conversion efficiency. Based on the latest financial reports, Bluebird bio Inc (BLUE) has a cash flow conversion efficiency ratio of 0.751x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.44 Million) by net assets ($-57.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bluebird bio Inc (2011–2024)
Cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024. This chart illustrates how Bluebird bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BLUE stock price and chart for real-time trading data and today's change.
Bluebird bio Inc Cash Flow Conversion Ratio Explained
Bluebird bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bluebird bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluebird bio Inc ranked by their cash flow conversion efficiency. Also see market cap of Bluebird bio Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
|
W5 Solutions AB
ST:W5
|
0.074x |
|
Promateris SA
RO:PPL
|
N/A |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
-0.435x |
|
Tuniu Corp
NASDAQ:TOUR
|
0.013x |
|
Hvidbjerg Bank
CO:HVID
|
0.002x |
|
VivoPower PLC
NASDAQ:VIVO
|
N/A |
Annual Cash Flow Conversion Efficiency for Bluebird bio Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024. Review cash generation quality of Bluebird bio Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.53 Million | $-260.02 Million | 8.246x | +782.46% |
| 2023-12-31 | $194.54 Million | $-235.05 Million | -1.208x | +32.79% |
| 2022-12-31 | $196.34 Million | $-352.95 Million | -1.798x | -5.85% |
| 2021-12-31 | $374.28 Million | $-635.64 Million | -1.698x | -389.27% |
| 2020-12-31 | $1.36 Billion | $-470.35 Million | -0.347x | +20.97% |
| 2019-12-31 | $1.28 Billion | $-564.38 Million | -0.439x | -100.26% |
| 2018-12-31 | $1.89 Billion | $-413.43 Million | -0.219x | -26.91% |
| 2017-12-31 | $1.62 Billion | $-280.55 Million | -0.173x | +20.77% |
| 2016-12-31 | $869.44 Million | $-189.65 Million | -0.218x | -88.48% |
| 2015-12-31 | $850.50 Million | $-98.43 Million | -0.116x | +4.76% |
| 2014-12-31 | $491.26 Million | $-59.69 Million | -0.122x | -142.41% |
| 2013-12-31 | $151.67 Million | $43.45 Million | 0.286x | -24.11% |
| 2012-12-31 | $-55.75 Million | $-21.04 Million | 0.377x | +72.13% |
| 2011-12-31 | $-55.71 Million | $-12.22 Million | 0.219x | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more